Evidence map›Paper›PMID 36578005›Full record

ArticleBMC pediatrics2022

Characteristics of medicine use for children with asthma in China: a nationwide population-based study.

Ping Wu, Baoping Xu, Adong Shen, Huasong Zeng, Kunling Shen

Open access · goldAbstract read
In one paragraph

Article in BMC pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Ping WuDepartment of Allergy, Immunology and Rheumatology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No. 318 Renmin Middle Road, Yuexiu District, Guangzhou, 510120, Guangdong, China.
Baoping XuChina National Clinical Research Center of Respiratory Diseases, Respiratory Department of Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No. 56 Nan Li Shi Road, Xicheng District, Beijing, 100045, China.
Adong ShenChina National Clinical Research Center of Respiratory Diseases, Respiratory Department of Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No. 56 Nan Li Shi Road, Xicheng District, Beijing, 100045, China.
Huasong ZengDepartment of Allergy, Immunology and Rheumatology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No. 318 Renmin Middle Road, Yuexiu District, Guangzhou, 510120, Guangdong, China. huasongxuqing@163.com.
Kunling ShenChina National Clinical Research Center of Respiratory Diseases, Respiratory Department of Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No. 56 Nan Li Shi Road, Xicheng District, Beijing, 100045, China. kunlingshen1717@163.com.
Capital Medical University · CNGuangzhou Medical University · CNBeijing Children’s Hospital · CN

Funding

Kunling Shen 2016YFC0901103Ping Wu 20210201029
6 · The paper itself

Abstract

objectiveTo analyze the asthma medication use in Chinese children of different age groups, regions, and levels of cities in China, based on the 2015 Healthcare Insurance Data in China.

methodsThe China Healthcare Insurance Research Association (CHIRA) database was searched for children from 0 to 14 years old diagnosed as asthma based on the "J45" and "J46" coded in ICD-10. A cross-sectional study design was employed.

resultsA total of 308,550 children were identified, all of whom were treated under the coverage of healthcare insurance. Among them, 2,468 children were eligible for inclusion in the present study. Compared with the current status of asthma care in European and American countries, under the guidelines for the diagnosis and treatment of asthma in China, the use percentages of ICS and short-acting β

conclusionThe asthma medication use was attributed to many factors, thus efforts are still needed to further popularize the GINA programs and China's guidelines for asthma diagnosis and treatment, especially in the Central and West China.

Indexed as

Anti-Asthmatic AgentsAsthmaAdministration, InhalationAdolescentChildChild, PreschoolChinaCross-Sectional StudiesHumansInfantInfant, NewbornTheophyllineAnti-Asthmatic AgentsTheophyllineAsthmaHealthcare insurance dataMedicationPediatrics

Identifiers

PMID36578005
PMCPMC9795755
OpenAlexW4313417188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.